Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LJPC

La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis

La Jolla Pharmaceutical logo

About La Jolla Pharmaceutical Stock (NASDAQ:LJPC)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$3.12
$6.22
52-Week Range
N/A
Volume
66,708 shs
Average Volume
158,476 shs
Market Capitalization
$155.11 million
P/E Ratio
51.84
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Remove Ads
Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Stock News Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
See More Headlines

LJPC Stock Analysis - Frequently Asked Questions

La Jolla Pharmaceutical (NASDAQ:LJPC) issued its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to analyst estimates of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%.

Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
5/16/2022
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:LJPC
Employees
61
Year Founded
N/A

Profitability

Trailing P/E Ratio
51.84
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$19.66 million
Pretax Margin
8.64%

Debt

Sales & Book Value

Annual Sales
$75.72 million
Price / Cash Flow
7.95
Book Value
($2.94) per share
Price / Book
N/A

Miscellaneous

Free Float
15,885,000
Market Cap
$155.11 million
Optionable
Optionable
Beta
2.39

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:LJPC) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners